These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 30039694)

  • 21. Omalizumab in the treatment of antihistamine-resistant chronic urticaria in adults.
    Gómez-Vera J; Gutiérrez-Ávila SA; Acosta-Gutiérrez DN; López-Tiro JJ; Bedolla-Barajas M
    Ann Allergy Asthma Immunol; 2016 Aug; 117(2):204-6. PubMed ID: 27369651
    [No Abstract]   [Full Text] [Related]  

  • 22. The relationship between allergen immunotherapy and omalizumab for treating asthma.
    Braido F; Corsico A; Rogkakou A; Ronzoni V; Baiardini I; Canonica GW
    Expert Rev Respir Med; 2015 Apr; 9(2):129-34. PubMed ID: 25578528
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Different Skin Prick Test Sensitization Patterns Do Not Influence the Response to Omalizumab in Severe Asthma.
    Sposato B; Scalese M; Milanese M; Masieri S; Cavaliere C; Latorre M; Scichilone N; Matucci A; Vultaggio A; Ricci A; Cresti A; Paggiaro PL
    J Investig Allergol Clin Immunol; 2017; 27(6):388-391. PubMed ID: 29199967
    [No Abstract]   [Full Text] [Related]  

  • 24. The discovery and development of omalizumab for the treatment of asthma.
    Licari A; Marseglia G; Castagnoli R; Marseglia A; Ciprandi G
    Expert Opin Drug Discov; 2015; 10(9):1033-42. PubMed ID: 25979110
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Omalizumab and Allergic Reactions.
    Ledford DK
    J Allergy Clin Immunol Pract; 2016; 4(1):187-8. PubMed ID: 26772933
    [No Abstract]   [Full Text] [Related]  

  • 26. [Omalizumab and allergen immunotherapy: A clinical report and review of the literature].
    Carrier C; Demoly P; Caimmi D
    Rev Mal Respir; 2019 Feb; 36(2):191-196. PubMed ID: 30396780
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunological intervention with anti-immunoglobulin-E antibody to prevent asthma exacerbations.
    Chanez P
    Eur Respir J; 2001 Aug; 18(2):249-50. PubMed ID: 11529279
    [No Abstract]   [Full Text] [Related]  

  • 28. Omalizumab in children with severe allergic disease: a case series.
    Crisafulli G; Caminiti L; Chiera F; Arasi S; Salzano G; Panasiti I; Barbalace A; Pajno GB
    Ital J Pediatr; 2019 Jan; 45(1):13. PubMed ID: 30642367
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Omalizumab, an additional therapy for allergic bronchopulmonary aspergillosis.
    Evans MO; Morris MJ; Coop CA; Evans SE
    Ann Allergy Asthma Immunol; 2015 Sep; 115(3):250-1. PubMed ID: 26162570
    [No Abstract]   [Full Text] [Related]  

  • 30. Utility of serum periostin and free IgE levels in evaluating responsiveness to omalizumab in patients with severe asthma.
    Tajiri T; Matsumoto H; Gon Y; Ito R; Hashimoto S; Izuhara K; Suzukawa M; Ohta K; Ono J; Ohta S; Ito I; Oguma T; Inoue H; Iwata T; Kanemitsu Y; Nagasaki T; Niimi A; Mishima M
    Allergy; 2016 Oct; 71(10):1472-9. PubMed ID: 27113353
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 'Real-life' effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review.
    Abraham I; Alhossan A; Lee CS; Kutbi H; MacDonald K
    Allergy; 2016 May; 71(5):593-610. PubMed ID: 26644231
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality.
    Holgate S; Bousquet J; Wenzel S; Fox H; Liu J; Castellsague J
    Curr Med Res Opin; 2001; 17(4):233-40. PubMed ID: 11922396
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systemic reaction rates with omalizumab, subcutaneous immunotherapy, and combination therapy in children with allergic asthma.
    Har D; Lee MJ
    Allergy Asthma Proc; 2019 Jan; 40(1):35-40. PubMed ID: 30582494
    [No Abstract]   [Full Text] [Related]  

  • 34. [Omalizumab for severe vernal keratoconjunctivitis].
    Callet M; Stolowy N; Zanin E; Denis D
    J Fr Ophtalmol; 2018 Dec; 41(10):e499-e500. PubMed ID: 30473237
    [No Abstract]   [Full Text] [Related]  

  • 35. How omalizumab came to be studied as a therapy for chronic spontaneous/idiopathic urticaria.
    Kaplan AP; Joseph K; Saini SS
    J Allergy Clin Immunol Pract; 2015; 3(4):648. PubMed ID: 26164583
    [No Abstract]   [Full Text] [Related]  

  • 36. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.
    Busse W; Corren J; Lanier BQ; McAlary M; Fowler-Taylor A; Cioppa GD; van As A; Gupta N
    J Allergy Clin Immunol; 2001 Aug; 108(2):184-90. PubMed ID: 11496232
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized trial of quilizumab in adults with refractory chronic spontaneous urticaria.
    Harris JM; Cabanski CR; Scheerens H; Samineni D; Bradley MS; Cochran C; Staubach P; Metz M; Sussman G; Maurer M
    J Allergy Clin Immunol; 2016 Dec; 138(6):1730-1732. PubMed ID: 27567329
    [No Abstract]   [Full Text] [Related]  

  • 38. Response to omalizumab in patients with severe allergic asthma: A real-life study.
    Zierau L; Walsted ES; Thomsen SF; Backer V
    Respir Med; 2017 Oct; 131():109-113. PubMed ID: 28947015
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation.
    Holgate S; Casale T; Wenzel S; Bousquet J; Deniz Y; Reisner C
    J Allergy Clin Immunol; 2005 Mar; 115(3):459-65. PubMed ID: 15753888
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study.
    Sheinkopf LE; Rafi AW; Do LT; Katz RM; Klaustermeyer WB
    Allergy Asthma Proc; 2008; 29(5):530-7. PubMed ID: 18926061
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.